<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01205776</url>
  </required_header>
  <id_info>
    <org_study_id>10-389</org_study_id>
    <nct_id>NCT01205776</nct_id>
  </id_info>
  <brief_title>EXCEL Clinical Trial</brief_title>
  <acronym>EXCEL</acronym>
  <official_title>Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the safety and efficacy of the commercially approved XIENCE Family Stent System
      (inclusive of XIENCE PRIME, XIENCE V, XIENCE Xpedition and XIENCE PRO [for use outside the
      United States [OUS] only]) in subjects with unprotected left main coronary artery disease by
      comparing to coronary artery bypass graft surgery.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</measure>
    <time_frame>3 years</time_frame>
    <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numberof Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</measure>
    <time_frame>3 years</time_frame>
    <description>Death:
Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).
Non-cardiac death is defined as a death not due to cardiac causes (as defined above).
Myocardial Infarction (MI) -Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Unplanned revascularization for ischemia: Any repeat revascularization of either a target vessel or non-target vessel with any of the above criteria for ischemia met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</measure>
    <time_frame>in-hospital (≤ 7 days of index-procedure)</time_frame>
    <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</measure>
    <time_frame>0 to 6 months</time_frame>
    <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</measure>
    <time_frame>in-hospital (≤ 7 days of index-procedure)</time_frame>
    <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</measure>
    <time_frame>0-30 days</time_frame>
    <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</measure>
    <time_frame>0 to 6 months</time_frame>
    <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</measure>
    <time_frame>in-hospital (≤ 7 days of index-procedure)</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</measure>
    <time_frame>0-30 days</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</measure>
    <time_frame>0 to 6 months</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Protocol Defined MI</measure>
    <time_frame>In-hospital (≤ 7 days of post index procedure)</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Protocol Defined MI</measure>
    <time_frame>0-30 days</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Protocol Defined MI</measure>
    <time_frame>0 to 6 months</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Protocol Defined MI</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Protocol Defined MI</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Protocol Defined MI</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</measure>
    <time_frame>in-hospital (≤ 7 days of index-procedure)</time_frame>
    <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</measure>
    <time_frame>0-30 days</time_frame>
    <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</measure>
    <time_frame>0 to 6 months</time_frame>
    <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Disability Following Stroke Event</measure>
    <time_frame>90 days ± 2 weeks</time_frame>
    <description>In case of an event of stroke disability at 90-days±2 weeks will be an overall measurement of severity of stroke as assessed by modified Rankin Scale (mRS) scale.
Stroke disability will be classified using an adaptation of the modified Rankin Scale as follows, the assessment of which will be based on the Modified Rankin Disability Questionnaire.
Scale 0; No stroke symptoms at all. (May have other complaints) Scale 1; No significant disability; symptoms present but no physical or other limitations.
Scale 2; Slight disability; limitations in participation in usual social roles, but independent for activities of daily living (ADL) Scale 3; Some need for assistance but able to walk without assistance Scale 4; Moderately severe disability; need for assistance with some basic ADL, but not requiring constant care Scale 5; Severe disability; requiring constant nursing care and attention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven Revascularizations (TLR,TVR and Non-TVR)</measure>
    <time_frame>in-hospital (≤ 7 days of index-procedure)</time_frame>
    <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven Revascularizations</measure>
    <time_frame>0-30 days</time_frame>
    <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven Revascularizations</measure>
    <time_frame>0 to 6 months</time_frame>
    <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven Revascularizations</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven Revascularizations</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven Revascularizations</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularizations (Ischemia-driven or Non Ischemia-driven)</measure>
    <time_frame>in-hospital (≤ 7 days of index-procedure)</time_frame>
    <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)</measure>
    <time_frame>0-30 days</time_frame>
    <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)</measure>
    <time_frame>0 to 6 months</time_frame>
    <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Major Adverse Events (MAE)</measure>
    <time_frame>in-hospital</time_frame>
    <description>Composite of death, myocardial infarction, stroke, transfusion of ≥ 2 units of blood, major arrhythmia, unplanned coronary revascularization for ischemia, any unplanned surgery or radiologic procedure, renal failure, sternal wound dehiscence, infection requiring antibiotics for treatment, intubation for &gt; 48 hours, or post-pericardiotomy syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent Thrombosis (ARC Definition) Definite/Probable</measure>
    <time_frame>Acute (&lt;= 24 hours)</time_frame>
    <description>Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.
Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&amp;presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive thrombus
Occlusive thrombus.
Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.
Probable stent thrombosis may occur after intracoronary stenting due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&amp;in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent Thrombosis (ARC Definition) Definite/ Probable</measure>
    <time_frame>Subacute (1-30 days)</time_frame>
    <description>Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.
Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&amp;presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive thrombus
Occlusive thrombus.
Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.
Probable stent thrombosis may occur after intracoronary stenting due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&amp;in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent Thrombosis (ARC Definition) Definite/Probable</measure>
    <time_frame>Early (0-30 days)</time_frame>
    <description>Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.
Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&amp;presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive thrombus
Occlusive thrombus.
Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.
Probable stent thrombosis may occur after intracoronary stenting due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&amp;in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent Thrombosis (ARC Definition) Definite/Probable</measure>
    <time_frame>Late (&gt;30 days - 1 year)</time_frame>
    <description>Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.
Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&amp;presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive thrombus
Occlusive thrombus.
Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.
Probable stent thrombosis may occur after intracoronary stenting due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&amp;in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent Thrombosis (ARC Definition) Definite/ Probable</measure>
    <time_frame>Very late (&gt;1 year)</time_frame>
    <description>Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.
Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&amp;presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive thrombus
Occlusive thrombus.
Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.
Probable stent thrombosis may occur after intracoronary stenting due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&amp;in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Graft Stenosis or Occlusion</measure>
    <time_frame>in-hospital (≤ 7 days of index-procedure)</time_frame>
    <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Graft Stenosis or Occlusion</measure>
    <time_frame>0-30 days</time_frame>
    <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Graft Stenosis or Occlusion</measure>
    <time_frame>0 to 6 months</time_frame>
    <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Graft Stenosis or Occlusion</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Graft Stenosis or Occlusion</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Graft Stenosis or Occlusion</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Requirement for Blood Product Transfusion</measure>
    <time_frame>30 days</time_frame>
    <description>All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are adjusted by 1 g/dl or 3%, respectively, for each unit of blood transfused. Therefore, the true change in hemoglobin or hematocrit if there has been an intervening transfusion between two blood measurements is calculated as follows:
Δ Hemoglobin = [baseline Hgb - post-transfusion Hgb] + [number of transfused units];
Δ Hematocrit = [baseline Hct - post-transfusion Hct] + [number of transfused units X 3].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Requirement for Blood Product Transfusion</measure>
    <time_frame>3 years</time_frame>
    <description>All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are adjusted by 1 g/dl or 3%, respectively, for each unit of blood transfused. Therefore, the true change in hemoglobin or hematocrit if there has been an intervening transfusion between two blood measurements is calculated as follows:
Δ Hemoglobin = [baseline Hgb - post-transfusion Hgb] + [number of transfused units];
Δ Hematocrit = [baseline Hct - post-transfusion Hct] + [number of transfused units X 3].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Bleeding will be classified by the TIMI hemorrhage classification
Severity:
Major:
Intracranial hemorrhage
A ≥5 g/dL decrease in the hemoglobin concentration
A ≥15% absolute decrease in the hematocrit
Minor:
Observed blood loss:
A ≥ 3 g/dL decrease in the hemoglobin concentration
A ≥ 10% absolute decrease in the hematocrit
No observed blood loss:
A ≥ 4 g/dL decrease in the hemoglobin concentration
A ≥ 12% absolute decrease in the hematocrit
Minimal:
• Any clinically overt sign of hemorrhage (including imaging) that is associated with a &lt; 3 g/dL decrease in hemoglobin concentration or &lt; 9% decrease in the hematocrit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding</measure>
    <time_frame>3 years</time_frame>
    <description>Bleeding will be classified by the TIMI hemorrhage classification
Severity:
Major:
Intracranial hemorrhage
A ≥5 g/dL decrease in the hemoglobin concentration
A ≥15% absolute decrease in the hematocrit
Minor:
Observed blood loss:
A ≥ 3 g/dL decrease in the hemoglobin concentration
A ≥ 10% absolute decrease in the hematocrit
No observed blood loss:
A ≥ 4 g/dL decrease in the hemoglobin concentration
A ≥ 12% absolute decrease in the hematocrit
Minimal:
• Any clinically overt sign of hemorrhage (including imaging) that is associated with a &lt; 3 g/dL decrease in hemoglobin concentration or &lt; 9% decrease in the hematocrit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Academic Research Consortium (BARC) Bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Type 0: No bleeding Type 1: Bleeding that is not actionable&amp;does not cause the patient to seek unscheduled performance of studies,hospitalization,or treatment by a healthcare professional Type 2: Any overt, actionable sign of hemorrhage that does not fit the criteria for type 3,4,or 5 but does meet at least 1 of the following criteria:requiring nonsurgical, medical intervention by a healthcare professional; leading to hospitalization or increased level of care; prompting evaluation.
Type 3 Type 3a
Overt bleeding plus hemoglobin drop of 3 to &lt; 5 g/dL
Any transfusion with overt bleeding Type 3b
Overt bleeding plus hemoglobin drop ≥5 g/dL*
Cardiac tamponade
Bleeding requiring surgical intervention for control
Bleeding requiring intravenous vasoactive agents Type 3c
Intracranial hemorrhage
Subcategories confirmed by autopsy or imaging or lumbar puncture
Intraocular bleed compromising vision Type 4: CABG-related bleeding Type 5: Fatal bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Academic Research Consortium (BARC) Bleeding</measure>
    <time_frame>3 years</time_frame>
    <description>Type 0: no bleeding Type 1: bleeding that is not actionable&amp;does not cause the patient to seek unscheduled performance of studies,hospitalization,or treatment by a healthcare professional Type 2: any overt, actionable sign of hemorrhage that does not fit the criteria for type 3,4,or 5 but does meet at least 1 of the following criteria:requiring nonsurgical, medical intervention by a healthcare professional; leading to hospitalization or increased level of care; prompting evaluation.
Type 3 Type 3a
Overt bleeding plus hemoglobin drop of 3 to &lt; 5 g/dL
Any transfusion with overt bleeding Type 3b
Overt bleeding plus hemoglobin drop ≥5 g/dL*
Cardiac tamponade
Bleeding requiring surgical intervention for control
Bleeding requiring intravenous vasoactive agents Type 3c
Intracranial hemorrhage
Subcategories confirmed by autopsy or imaging or lumbar puncture
Intraocular bleed compromising vision Type 4: CABG-related bleeding Type 5: fatal bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Adverse Events (MAE)</measure>
    <time_frame>30 days</time_frame>
    <description>death
myocardial infarction
stroke
Transfusion of ≥2 units of blood
TIMI major or minor bleeding
major arrhythmia
unplanned coronary revascularization for ischemia
any unplanned surgery or therapeutic radiologic procedure
renal failure
sternal wound dehiscence
infection requiring antibiotics for treatment
intubation for &gt; 48 hours
post-pericardiotomy syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete Revascularization (Residual = 0)</measure>
    <time_frame>At Baseline</time_frame>
    <description>Complete anatomic revascularization requires revascularization of all vessels ≥2.0 mm reference vessel diameter with a DS ≥60% (both as measured by core angiographic laboratory analysis).
-While this will be the pre-specified criteria for anatomically significant lesions, sensitivity analysis will be performed using different criteria (e.g. ≥2.5 mm vessels, DS ≥70%, etc.)
From the baseline angiogram, the angiographic core lab will identify and designate those lesions and vessels requiring revascularization in all subjects according to this definition, prior to knowledge of the extent of actual revascularization.
Following PCI, the angiographic core lab will determine the extent of revascularization (vessels with TIMI 2or3 flow post procedure with a core laboratory DS &lt;50% considered successfully revascularized).
Following CABG, the angiographic core lab will determine the extent of revascularization or if there is a repeat angiogram during the index hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Definite Stent Thrombosis (ST) or Symptomatic Graft Occlusion</measure>
    <time_frame>In-hospital (≤ 7 days of post index procedure)</time_frame>
    <description>- Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
-Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion</measure>
    <time_frame>1 year</time_frame>
    <description>- Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
-Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion</measure>
    <time_frame>2 years</time_frame>
    <description>- Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
-Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion</measure>
    <time_frame>3 years</time_frame>
    <description>- Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
-Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1905</enrollment>
  <condition>Chronic Coronary Occlusion</condition>
  <condition>Unprotected Left Main Coronary Artery Disease</condition>
  <condition>Stent Thrombosis</condition>
  <condition>Vascular Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coronary Artery Bypass Graft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Those patients receiving CABG</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous Coronary Intervention</intervention_name>
    <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG</intervention_name>
    <description>Those patients receiving CABG</description>
    <arm_group_label>Coronary Artery Bypass Graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        * Inclusion criteria for RCT:

          -  Unprotected left main coronary artery (ULMCA) disease with angiographic diameter
             stenosis (DS) ≥70% requiring revascularization, or

          -  ULMCA disease with agniographic DS &gt;=50% but &lt; 70% requiring revascularization, with
             one or more of the following present:

               -  Non-invasive evidence of ischemia referable to a hemodynamically significant left
                  main lesion (large area of ischemia in both the LAD and LCX territories, or in
                  either the LAD or LCX territory in the absence of other obstructive coronary
                  artery disease to explain the LAD or LCX defect), or stress-induced hypotension
                  or stress-induced fall in LVEF, or stress-induced transient ischemic dilatation
                  of the left ventricle or stress-induced thallium/technetiumlung uptake, and/or

               -  IVUS minimum lumen area (MLA) &lt;= 6.0mm2, and/or

               -  Fractional Flow Reserve (FFR) &lt;=0.80

          -  Left Main Equivalent Disease

          -  Clinical and anatomic eligibility for both PCI and CABG

          -  Silent ischemia, stable angina, unstable angina or recent MI

          -  Ability to sign informed consent and comply with all study procedures including
             follow-up for at least three years

        Exclusion Criteria:

        * Clinical exclusion criteria:

          -  Prior PCI of the left main trunk at any time prior to randomization

          -  Prior PCI of any other coronary artery lesions within one year prior to randomization

          -  Prior CABG at any time prior to randomization

          -  Need for any concomitant cardiac surgery other than CABG, or intent that if the
             subject randomizes to surgery, any cardiac surgical procedure other than isolated CABG
             will be performed

          -  CK-MB greater than the local laboratory upper limit of normal or recent MI with CK-MB
             still elevated

          -  Subjects unable to tolerate, obtain or comply with dual antiplatelet therapy for at
             least one year

          -  Subjects requiring or who may require additional surgery within one year

          -  The presence of any clinical condition(s) which leads the participating interventional
             cardiologist to believe that clinical equipoise is not present

          -  The presence of any clinical condition(s) which leads the participating cardiac
             surgeon to believe that clinical equipoise is not present

          -  Pregnancy or intention to become pregnant

          -  Non cardiac co-morbidities with life expectancy less than 3 years

          -  Other investigational drug or device studies that have not reached their primary
             endpoint

          -  Vulnerable population who in the judgment of the investigator is unable to give
             Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances
             or lack of autonomy. This may include: Individuals with mental disability, persons in
             nursing homes, children, impoverished persons, persons in emergency situations,
             homeless persons, nomads, refugees, and those permanently incapable of giving informed
             consent. Vulnerable populations also may include members of a group with a
             hierarchical structure such as university students, subordinate hospital and
             laboratory personnel, employees of the Sponsor, members of the armed forces, and
             persons kept in detention

        Angiographic exclusion criteria:

          -  Left main diameter stenosis &lt;50%

          -  SYNTAX score ≥33

          -  Left main reference vessel diameter &lt;2.25 mm or &gt;4.25 mm

          -  The presence of specific coronary lesion characteristics or other cardiac condition(s)
             which leads the participating interventional cardiologist to believe that clinical
             equipoise is not present

          -  The presence of specific coronary lesion characteristics or other cardiac condition(s)
             which leads the participating cardiac surgeon to believe that clinical equipoise is
             not present
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg W Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick W Serruys, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Sabik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinical Main Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. Pieter Kappetein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abbott Vascular</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2010</study_first_submitted>
  <study_first_submitted_qc>September 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2010</study_first_posted>
  <results_first_submitted>March 1, 2018</results_first_submitted>
  <results_first_submitted_qc>March 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2018</results_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug eluting stents</keyword>
  <keyword>Stents</keyword>
  <keyword>Unprotected Left Main Coronary Artery Disease</keyword>
  <keyword>Coronary artery bypass graft surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
    <mesh_term>Coronary Occlusion</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 1905 subjects were randomized (Percutaneous Coronary Intervention (PCI): 948 &amp; Coronary Artery Bypass Graft (CABG) 957) between September 29, 2010 and March 6, 2014. Five hundred and forty-nine (549) subjects were from 56 U.S. sites and 1356 subjects were from 70 international sites,for a total of 126 enrolling sites.</recruitment_details>
      <pre_assignment_details>The original EXCEL study consisted of a randomized clinical trial (RCT) (n=2600) &amp; a Universal Registry (n=1000). In February 2014,a decision was made to cap enrollment in the RCT at approximately 1900.The change in scope of the study design was not due to any device or subject safety issues.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Percutaneous Coronary Intervention (PCI)</title>
          <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
        </group>
        <group group_id="P2">
          <title>Coronary Artery Bypass Graft (CABG)</title>
          <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>1 Month Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="948"/>
                <participants group_id="P2" count="957"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="943"/>
                <participants group_id="P2" count="945"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>2 Years Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="943"/>
                <participants group_id="P2" count="945"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="927"/>
                <participants group_id="P2" count="913"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>3 Years Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="927"/>
                <participants group_id="P2" count="913"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="911"/>
                <participants group_id="P2" count="889"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Percutaneous Coronary Intervention (PCI)</title>
          <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
        </group>
        <group group_id="B2">
          <title>Coronary Artery Bypass Graft (CABG)</title>
          <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="948"/>
            <count group_id="B2" value="957"/>
            <count group_id="B3" value="1905"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.0" spread="9.6"/>
                    <measurement group_id="B2" value="65.9" spread="9.5"/>
                    <measurement group_id="B3" value="66.0" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="722"/>
                    <measurement group_id="B2" value="742"/>
                    <measurement group_id="B3" value="1464"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="844"/>
                    <measurement group_id="B2" value="853"/>
                    <measurement group_id="B3" value="1697"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="534"/>
                    <measurement group_id="B2" value="541"/>
                    <measurement group_id="B3" value="1075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="278"/>
                    <measurement group_id="B2" value="271"/>
                    <measurement group_id="B3" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Southeast Asia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</title>
        <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</title>
          <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numberof Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</title>
        <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Numberof Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</title>
          <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>p-value and 95% CI of the Difference derived from the Com-Nougue Approach of non-inferiority for two Kaplan-Meier Failure rates with a non-inferiority margin of 2% at the 0.05 level of significance.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value and 95% CI of the Difference derived from the Com-Nougue Approach of non-inferiority for two Kaplan-Meier Failure rates with a non-inferiority margin of 2% at the 0.05 level of significance.</p_value_desc>
            <method>Com-Nougue</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>-3.1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</title>
        <description>Death:
Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).
Non-cardiac death is defined as a death not due to cardiac causes (as defined above).
Myocardial Infarction (MI) -Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Unplanned revascularization for ischemia: Any repeat revascularization of either a target vessel or non-target vessel with any of the above criteria for ischemia met.</description>
        <time_frame>3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</title>
          <description>Death:
Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).
Non-cardiac death is defined as a death not due to cardiac causes (as defined above).
Myocardial Infarction (MI) -Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Unplanned revascularization for ischemia: Any repeat revascularization of either a target vessel or non-target vessel with any of the above criteria for ischemia met.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>p-value and 95% CI of the Difference derived from the Com-Nougue Approach of non-inferiority for two Kaplan-Meier Failure rates with a non-inferiority margin of 8.4% at the 0.05 level of significance.</non_inferiority_desc>
            <p_value>0.011</p_value>
            <p_value_desc>p-value and 95% CI of the Difference derived from the Com-Nougue Approach of non-inferiority for two Kaplan-Meier Failure rates with a non-inferiority margin of 8.4% at the 0.05 level of significance.</p_value_desc>
            <method>Com-Nougue Approach</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>4.0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</title>
        <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
        <time_frame>in-hospital (≤ 7 days of index-procedure)</time_frame>
        <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</title>
          <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
          <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</title>
        <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
        <time_frame>0 to 6 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</title>
          <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</title>
        <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</title>
          <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</title>
        <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</title>
          <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</title>
        <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke</title>
          <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</title>
        <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
        <time_frame>in-hospital (≤ 7 days of index-procedure)</time_frame>
        <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</title>
          <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
          <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</title>
        <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
        <time_frame>0-30 days</time_frame>
        <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</title>
          <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
          <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</title>
        <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
        <time_frame>0 to 6 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</title>
          <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</title>
        <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</title>
          <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</title>
        <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia</title>
          <description>All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.
Myocardial Infarction (MI):
Q wave MI: Development of new, pathological Q wave on the ECG.
Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.
Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>in-hospital (≤ 7 days of index-procedure)</time_frame>
        <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0-30 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 6 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Protocol Defined MI</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>In-hospital (≤ 7 days of post index procedure)</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Protocol Defined MI</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Protocol Defined MI</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0-30 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Protocol Defined MI</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Protocol Defined MI</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0 to 6 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Protocol Defined MI</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Protocol Defined MI</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Protocol Defined MI</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Protocol Defined MI</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Protocol Defined MI</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Protocol Defined MI</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Protocol Defined MI</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</title>
        <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
        <time_frame>in-hospital (≤ 7 days of index-procedure)</time_frame>
        <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</title>
          <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
          <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</title>
        <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
        <time_frame>0-30 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</title>
          <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</title>
        <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
        <time_frame>0 to 6 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</title>
          <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</title>
        <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</title>
          <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</title>
        <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</title>
          <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</title>
        <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)</title>
          <description>Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.
Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.
All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Disability Following Stroke Event</title>
        <description>In case of an event of stroke disability at 90-days±2 weeks will be an overall measurement of severity of stroke as assessed by modified Rankin Scale (mRS) scale.
Stroke disability will be classified using an adaptation of the modified Rankin Scale as follows, the assessment of which will be based on the Modified Rankin Disability Questionnaire.
Scale 0; No stroke symptoms at all. (May have other complaints) Scale 1; No significant disability; symptoms present but no physical or other limitations.
Scale 2; Slight disability; limitations in participation in usual social roles, but independent for activities of daily living (ADL) Scale 3; Some need for assistance but able to walk without assistance Scale 4; Moderately severe disability; need for assistance with some basic ADL, but not requiring constant care Scale 5; Severe disability; requiring constant nursing care and attention.</description>
        <time_frame>90 days ± 2 weeks</time_frame>
        <population>ITT population. Analysis population includes subjects who had follow-up data at that time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Disability Following Stroke Event</title>
          <description>In case of an event of stroke disability at 90-days±2 weeks will be an overall measurement of severity of stroke as assessed by modified Rankin Scale (mRS) scale.
Stroke disability will be classified using an adaptation of the modified Rankin Scale as follows, the assessment of which will be based on the Modified Rankin Disability Questionnaire.
Scale 0; No stroke symptoms at all. (May have other complaints) Scale 1; No significant disability; symptoms present but no physical or other limitations.
Scale 2; Slight disability; limitations in participation in usual social roles, but independent for activities of daily living (ADL) Scale 3; Some need for assistance but able to walk without assistance Scale 4; Moderately severe disability; need for assistance with some basic ADL, but not requiring constant care Scale 5; Severe disability; requiring constant nursing care and attention.</description>
          <population>ITT population. Analysis population includes subjects who had follow-up data at that time period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven Revascularizations (TLR,TVR and Non-TVR)</title>
        <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
        <time_frame>in-hospital (≤ 7 days of index-procedure)</time_frame>
        <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia Driven Revascularizations (TLR,TVR and Non-TVR)</title>
          <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
          <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven Revascularizations</title>
        <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
        <time_frame>0-30 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia Driven Revascularizations</title>
          <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven Revascularizations</title>
        <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
        <time_frame>0 to 6 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia Driven Revascularizations</title>
          <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven Revascularizations</title>
        <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia Driven Revascularizations</title>
          <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven Revascularizations</title>
        <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia Driven Revascularizations</title>
          <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven Revascularizations</title>
        <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia Driven Revascularizations</title>
          <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion; or
Ischemic ECG changes at rest in a distribution consistent with the target vessel; or
Typical ischemic symptoms referable to the target lesion; or
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%; or
Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularizations (Ischemia-driven or Non Ischemia-driven)</title>
        <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
        <time_frame>in-hospital (≤ 7 days of index-procedure)</time_frame>
        <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularizations (Ischemia-driven or Non Ischemia-driven)</title>
          <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
          <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)</title>
        <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
        <time_frame>0-30 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)</title>
          <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)</title>
        <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
        <time_frame>0 to 6 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)</title>
          <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)</title>
        <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)</title>
          <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)</title>
        <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)</title>
          <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)</title>
        <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)</title>
          <description>A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:
A positive functional study corresponding to the area served by the target lesion;
Ischemic ECG changes at rest in a distribution consistent with the target vessel;
Typical ischemic symptoms referable to the target lesion;
IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm^2 for non left main lesions or ≤ 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the
plaque burden must also be ≥ 60%;
FFR of the target lesion ≤ 0.80
A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Major Adverse Events (MAE)</title>
        <description>Composite of death, myocardial infarction, stroke, transfusion of ≥ 2 units of blood, major arrhythmia, unplanned coronary revascularization for ischemia, any unplanned surgery or radiologic procedure, renal failure, sternal wound dehiscence, infection requiring antibiotics for treatment, intubation for &gt; 48 hours, or post-pericardiotomy syndrome.</description>
        <time_frame>in-hospital</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Major Adverse Events (MAE)</title>
          <description>Composite of death, myocardial infarction, stroke, transfusion of ≥ 2 units of blood, major arrhythmia, unplanned coronary revascularization for ischemia, any unplanned surgery or radiologic procedure, renal failure, sternal wound dehiscence, infection requiring antibiotics for treatment, intubation for &gt; 48 hours, or post-pericardiotomy syndrome.</description>
          <population>ITT Population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transfusion of &gt;= 2 units blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI major or minor bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unplanned coronary revascularization for ischemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unplanned surgery/therapeutic radiologic procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sternal wound dehiscence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection requiring antibiotics for treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intubation for &gt; 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-pericardiotomy syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent Thrombosis (ARC Definition) Definite/Probable</title>
        <description>Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.
Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&amp;presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive thrombus
Occlusive thrombus.
Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.
Probable stent thrombosis may occur after intracoronary stenting due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&amp;in the absence of any other obvious cause.</description>
        <time_frame>Acute (&lt;= 24 hours)</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis (ARC Definition) Definite/Probable</title>
          <description>Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.
Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&amp;presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive thrombus
Occlusive thrombus.
Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.
Probable stent thrombosis may occur after intracoronary stenting due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&amp;in the absence of any other obvious cause.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent Thrombosis (ARC Definition) Definite/ Probable</title>
        <description>Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.
Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&amp;presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive thrombus
Occlusive thrombus.
Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.
Probable stent thrombosis may occur after intracoronary stenting due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&amp;in the absence of any other obvious cause.</description>
        <time_frame>Subacute (1-30 days)</time_frame>
        <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis (ARC Definition) Definite/ Probable</title>
          <description>Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.
Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&amp;presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive thrombus
Occlusive thrombus.
Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.
Probable stent thrombosis may occur after intracoronary stenting due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&amp;in the absence of any other obvious cause.</description>
          <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent Thrombosis (ARC Definition) Definite/Probable</title>
        <description>Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.
Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&amp;presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive thrombus
Occlusive thrombus.
Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.
Probable stent thrombosis may occur after intracoronary stenting due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&amp;in the absence of any other obvious cause.</description>
        <time_frame>Early (0-30 days)</time_frame>
        <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis (ARC Definition) Definite/Probable</title>
          <description>Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.
Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&amp;presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive thrombus
Occlusive thrombus.
Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.
Probable stent thrombosis may occur after intracoronary stenting due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&amp;in the absence of any other obvious cause.</description>
          <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent Thrombosis (ARC Definition) Definite/Probable</title>
        <description>Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.
Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&amp;presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive thrombus
Occlusive thrombus.
Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.
Probable stent thrombosis may occur after intracoronary stenting due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&amp;in the absence of any other obvious cause.</description>
        <time_frame>Late (&gt;30 days - 1 year)</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis (ARC Definition) Definite/Probable</title>
          <description>Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.
Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&amp;presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive thrombus
Occlusive thrombus.
Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.
Probable stent thrombosis may occur after intracoronary stenting due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&amp;in the absence of any other obvious cause.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent Thrombosis (ARC Definition) Definite/ Probable</title>
        <description>Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.
Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&amp;presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive thrombus
Occlusive thrombus.
Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.
Probable stent thrombosis may occur after intracoronary stenting due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&amp;in the absence of any other obvious cause.</description>
        <time_frame>Very late (&gt;1 year)</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis (ARC Definition) Definite/ Probable</title>
          <description>Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.
Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&amp;presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive thrombus
Occlusive thrombus.
Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.
Probable stent thrombosis may occur after intracoronary stenting due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&amp;in the absence of any other obvious cause.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Graft Stenosis or Occlusion</title>
        <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
        <time_frame>in-hospital (≤ 7 days of index-procedure)</time_frame>
        <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Graft Stenosis or Occlusion</title>
          <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
          <population>ITT population. Subjects without the required follow-up are excluded from the time period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Graft Stenosis or Occlusion</title>
        <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
        <time_frame>0-30 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Graft Stenosis or Occlusion</title>
          <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Graft Stenosis or Occlusion</title>
        <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
        <time_frame>0 to 6 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Graft Stenosis or Occlusion</title>
          <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Graft Stenosis or Occlusion</title>
        <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Graft Stenosis or Occlusion</title>
          <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Graft Stenosis or Occlusion</title>
        <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Graft Stenosis or Occlusion</title>
          <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Graft Stenosis or Occlusion</title>
        <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Graft Stenosis or Occlusion</title>
          <description>Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Requirement for Blood Product Transfusion</title>
        <description>All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are adjusted by 1 g/dl or 3%, respectively, for each unit of blood transfused. Therefore, the true change in hemoglobin or hematocrit if there has been an intervening transfusion between two blood measurements is calculated as follows:
Δ Hemoglobin = [baseline Hgb – post-transfusion Hgb] + [number of transfused units];
Δ Hematocrit = [baseline Hct – post-transfusion Hct] + [number of transfused units X 3].</description>
        <time_frame>30 days</time_frame>
        <population>ITT population. Analysis population includes subjects who had follow-up data at that time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Requirement for Blood Product Transfusion</title>
          <description>All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are adjusted by 1 g/dl or 3%, respectively, for each unit of blood transfused. Therefore, the true change in hemoglobin or hematocrit if there has been an intervening transfusion between two blood measurements is calculated as follows:
Δ Hemoglobin = [baseline Hgb – post-transfusion Hgb] + [number of transfused units];
Δ Hematocrit = [baseline Hct – post-transfusion Hct] + [number of transfused units X 3].</description>
          <population>ITT population. Analysis population includes subjects who had follow-up data at that time period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Requirement for Blood Product Transfusion</title>
        <description>All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are adjusted by 1 g/dl or 3%, respectively, for each unit of blood transfused. Therefore, the true change in hemoglobin or hematocrit if there has been an intervening transfusion between two blood measurements is calculated as follows:
Δ Hemoglobin = [baseline Hgb – post-transfusion Hgb] + [number of transfused units];
Δ Hematocrit = [baseline Hct – post-transfusion Hct] + [number of transfused units X 3].</description>
        <time_frame>3 years</time_frame>
        <population>ITT population. Analysis population includes subjects who had follow-up data at that time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Requirement for Blood Product Transfusion</title>
          <description>All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are adjusted by 1 g/dl or 3%, respectively, for each unit of blood transfused. Therefore, the true change in hemoglobin or hematocrit if there has been an intervening transfusion between two blood measurements is calculated as follows:
Δ Hemoglobin = [baseline Hgb – post-transfusion Hgb] + [number of transfused units];
Δ Hematocrit = [baseline Hct – post-transfusion Hct] + [number of transfused units X 3].</description>
          <population>ITT population. Analysis population includes subjects who had follow-up data at that time period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding</title>
        <description>Bleeding will be classified by the TIMI hemorrhage classification
Severity:
Major:
Intracranial hemorrhage
A ≥5 g/dL decrease in the hemoglobin concentration
A ≥15% absolute decrease in the hematocrit
Minor:
Observed blood loss:
A ≥ 3 g/dL decrease in the hemoglobin concentration
A ≥ 10% absolute decrease in the hematocrit
No observed blood loss:
A ≥ 4 g/dL decrease in the hemoglobin concentration
A ≥ 12% absolute decrease in the hematocrit
Minimal:
• Any clinically overt sign of hemorrhage (including imaging) that is associated with a &lt; 3 g/dL decrease in hemoglobin concentration or &lt; 9% decrease in the hematocrit.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population. Analysis population includes subjects who had follow-up data at that time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding</title>
          <description>Bleeding will be classified by the TIMI hemorrhage classification
Severity:
Major:
Intracranial hemorrhage
A ≥5 g/dL decrease in the hemoglobin concentration
A ≥15% absolute decrease in the hematocrit
Minor:
Observed blood loss:
A ≥ 3 g/dL decrease in the hemoglobin concentration
A ≥ 10% absolute decrease in the hematocrit
No observed blood loss:
A ≥ 4 g/dL decrease in the hemoglobin concentration
A ≥ 12% absolute decrease in the hematocrit
Minimal:
• Any clinically overt sign of hemorrhage (including imaging) that is associated with a &lt; 3 g/dL decrease in hemoglobin concentration or &lt; 9% decrease in the hematocrit.</description>
          <population>ITT population. Analysis population includes subjects who had follow-up data at that time period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding</title>
        <description>Bleeding will be classified by the TIMI hemorrhage classification
Severity:
Major:
Intracranial hemorrhage
A ≥5 g/dL decrease in the hemoglobin concentration
A ≥15% absolute decrease in the hematocrit
Minor:
Observed blood loss:
A ≥ 3 g/dL decrease in the hemoglobin concentration
A ≥ 10% absolute decrease in the hematocrit
No observed blood loss:
A ≥ 4 g/dL decrease in the hemoglobin concentration
A ≥ 12% absolute decrease in the hematocrit
Minimal:
• Any clinically overt sign of hemorrhage (including imaging) that is associated with a &lt; 3 g/dL decrease in hemoglobin concentration or &lt; 9% decrease in the hematocrit.</description>
        <time_frame>3 years</time_frame>
        <population>ITT population. Analysis population includes subjects who had follow-up data at that time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding</title>
          <description>Bleeding will be classified by the TIMI hemorrhage classification
Severity:
Major:
Intracranial hemorrhage
A ≥5 g/dL decrease in the hemoglobin concentration
A ≥15% absolute decrease in the hematocrit
Minor:
Observed blood loss:
A ≥ 3 g/dL decrease in the hemoglobin concentration
A ≥ 10% absolute decrease in the hematocrit
No observed blood loss:
A ≥ 4 g/dL decrease in the hemoglobin concentration
A ≥ 12% absolute decrease in the hematocrit
Minimal:
• Any clinically overt sign of hemorrhage (including imaging) that is associated with a &lt; 3 g/dL decrease in hemoglobin concentration or &lt; 9% decrease in the hematocrit.</description>
          <population>ITT population. Analysis population includes subjects who had follow-up data at that time period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Academic Research Consortium (BARC) Bleeding</title>
        <description>Type 0: No bleeding Type 1: Bleeding that is not actionable&amp;does not cause the patient to seek unscheduled performance of studies,hospitalization,or treatment by a healthcare professional Type 2: Any overt, actionable sign of hemorrhage that does not fit the criteria for type 3,4,or 5 but does meet at least 1 of the following criteria:requiring nonsurgical, medical intervention by a healthcare professional; leading to hospitalization or increased level of care; prompting evaluation.
Type 3 Type 3a
Overt bleeding plus hemoglobin drop of 3 to &lt; 5 g/dL
Any transfusion with overt bleeding Type 3b
Overt bleeding plus hemoglobin drop ≥5 g/dL*
Cardiac tamponade
Bleeding requiring surgical intervention for control
Bleeding requiring intravenous vasoactive agents Type 3c
Intracranial hemorrhage
Subcategories confirmed by autopsy or imaging or lumbar puncture
Intraocular bleed compromising vision Type 4: CABG-related bleeding Type 5: Fatal bleeding</description>
        <time_frame>30 days</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Academic Research Consortium (BARC) Bleeding</title>
          <description>Type 0: No bleeding Type 1: Bleeding that is not actionable&amp;does not cause the patient to seek unscheduled performance of studies,hospitalization,or treatment by a healthcare professional Type 2: Any overt, actionable sign of hemorrhage that does not fit the criteria for type 3,4,or 5 but does meet at least 1 of the following criteria:requiring nonsurgical, medical intervention by a healthcare professional; leading to hospitalization or increased level of care; prompting evaluation.
Type 3 Type 3a
Overt bleeding plus hemoglobin drop of 3 to &lt; 5 g/dL
Any transfusion with overt bleeding Type 3b
Overt bleeding plus hemoglobin drop ≥5 g/dL*
Cardiac tamponade
Bleeding requiring surgical intervention for control
Bleeding requiring intravenous vasoactive agents Type 3c
Intracranial hemorrhage
Subcategories confirmed by autopsy or imaging or lumbar puncture
Intraocular bleed compromising vision Type 4: CABG-related bleeding Type 5: Fatal bleeding</description>
          <population>ITT Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Academic Research Consortium (BARC) Bleeding</title>
        <description>Type 0: no bleeding Type 1: bleeding that is not actionable&amp;does not cause the patient to seek unscheduled performance of studies,hospitalization,or treatment by a healthcare professional Type 2: any overt, actionable sign of hemorrhage that does not fit the criteria for type 3,4,or 5 but does meet at least 1 of the following criteria:requiring nonsurgical, medical intervention by a healthcare professional; leading to hospitalization or increased level of care; prompting evaluation.
Type 3 Type 3a
Overt bleeding plus hemoglobin drop of 3 to &lt; 5 g/dL
Any transfusion with overt bleeding Type 3b
Overt bleeding plus hemoglobin drop ≥5 g/dL*
Cardiac tamponade
Bleeding requiring surgical intervention for control
Bleeding requiring intravenous vasoactive agents Type 3c
Intracranial hemorrhage
Subcategories confirmed by autopsy or imaging or lumbar puncture
Intraocular bleed compromising vision Type 4: CABG-related bleeding Type 5: fatal bleeding</description>
        <time_frame>3 years</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Academic Research Consortium (BARC) Bleeding</title>
          <description>Type 0: no bleeding Type 1: bleeding that is not actionable&amp;does not cause the patient to seek unscheduled performance of studies,hospitalization,or treatment by a healthcare professional Type 2: any overt, actionable sign of hemorrhage that does not fit the criteria for type 3,4,or 5 but does meet at least 1 of the following criteria:requiring nonsurgical, medical intervention by a healthcare professional; leading to hospitalization or increased level of care; prompting evaluation.
Type 3 Type 3a
Overt bleeding plus hemoglobin drop of 3 to &lt; 5 g/dL
Any transfusion with overt bleeding Type 3b
Overt bleeding plus hemoglobin drop ≥5 g/dL*
Cardiac tamponade
Bleeding requiring surgical intervention for control
Bleeding requiring intravenous vasoactive agents Type 3c
Intracranial hemorrhage
Subcategories confirmed by autopsy or imaging or lumbar puncture
Intraocular bleed compromising vision Type 4: CABG-related bleeding Type 5: fatal bleeding</description>
          <population>ITT Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Adverse Events (MAE)</title>
        <description>death
myocardial infarction
stroke
Transfusion of ≥2 units of blood
TIMI major or minor bleeding
major arrhythmia
unplanned coronary revascularization for ischemia
any unplanned surgery or therapeutic radiologic procedure
renal failure
sternal wound dehiscence
infection requiring antibiotics for treatment
intubation for &gt; 48 hours
post-pericardiotomy syndrome</description>
        <time_frame>30 days</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Adverse Events (MAE)</title>
          <description>death
myocardial infarction
stroke
Transfusion of ≥2 units of blood
TIMI major or minor bleeding
major arrhythmia
unplanned coronary revascularization for ischemia
any unplanned surgery or therapeutic radiologic procedure
renal failure
sternal wound dehiscence
infection requiring antibiotics for treatment
intubation for &gt; 48 hours
post-pericardiotomy syndrome</description>
          <population>ITT Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transfusion of &gt;= 2 units blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI major or minor bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unplanned coronary revascularization for ischemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unplanned surgery/therapeutic radiologic procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sternal wound dehiscence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection requiring antibiotics for treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intubation for &gt; 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-pericardiotomy syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete Revascularization (Residual = 0)</title>
        <description>Complete anatomic revascularization requires revascularization of all vessels ≥2.0 mm reference vessel diameter with a DS ≥60% (both as measured by core angiographic laboratory analysis).
-While this will be the pre-specified criteria for anatomically significant lesions, sensitivity analysis will be performed using different criteria (e.g. ≥2.5 mm vessels, DS ≥70%, etc.)
From the baseline angiogram, the angiographic core lab will identify and designate those lesions and vessels requiring revascularization in all subjects according to this definition, prior to knowledge of the extent of actual revascularization.
Following PCI, the angiographic core lab will determine the extent of revascularization (vessels with TIMI 2or3 flow post procedure with a core laboratory DS &lt;50% considered successfully revascularized).
Following CABG, the angiographic core lab will determine the extent of revascularization or if there is a repeat angiogram during the index hospitalization.</description>
        <time_frame>At Baseline</time_frame>
        <population>Not all PCI patients have Baseline and Post-PCI Syntax score assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Revascularization (Residual = 0)</title>
          <description>Complete anatomic revascularization requires revascularization of all vessels ≥2.0 mm reference vessel diameter with a DS ≥60% (both as measured by core angiographic laboratory analysis).
-While this will be the pre-specified criteria for anatomically significant lesions, sensitivity analysis will be performed using different criteria (e.g. ≥2.5 mm vessels, DS ≥70%, etc.)
From the baseline angiogram, the angiographic core lab will identify and designate those lesions and vessels requiring revascularization in all subjects according to this definition, prior to knowledge of the extent of actual revascularization.
Following PCI, the angiographic core lab will determine the extent of revascularization (vessels with TIMI 2or3 flow post procedure with a core laboratory DS &lt;50% considered successfully revascularized).
Following CABG, the angiographic core lab will determine the extent of revascularization or if there is a repeat angiogram during the index hospitalization.</description>
          <population>Not all PCI patients have Baseline and Post-PCI Syntax score assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="917"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Definite Stent Thrombosis (ST) or Symptomatic Graft Occlusion</title>
        <description>- Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
-Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
        <time_frame>In-hospital (≤ 7 days of post index procedure)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Definite Stent Thrombosis (ST) or Symptomatic Graft Occlusion</title>
          <description>- Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
-Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion</title>
        <description>- Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
-Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion</title>
          <description>- Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
-Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion</title>
        <description>- Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
-Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion</title>
          <description>- Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
-Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion</title>
        <description>- Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
-Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention (PCI)</title>
            <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
          </group>
          <group group_id="O2">
            <title>Coronary Artery Bypass Graft (CABG)</title>
            <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion</title>
          <description>- Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
-Symptomatic graft occlusion: Ischemic symptoms in the presence of ≥50% diameter stenosis in a coronary bypass graft.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="948"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Percutaneous Coronary Intervention (PCI)</title>
          <description>Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS</description>
        </group>
        <group group_id="E2">
          <title>Coronary Artery Bypass Graft (CABG)</title>
          <description>Those patients receiving Coronary Artery Bypass Graft (CABG)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="506" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="507" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Bleeding/blood disorder : Other</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Retroperitoneal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Abrupt closure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Angina pectoris (includes atypical angina and cardiac chest pain)</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Asystole</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardiac : Other</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardiac functional test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardiac valve disorder/disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Conduction disorder (including AV block, BBB)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary arteriospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery in-stent restenosis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery reocclusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary stent thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>No-reflow phenomenon/slow flow</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Plaque shift (tissue breakdown associated with device)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia (sustained)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>electrocardiogram (ECG) abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other : Endocrine disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Colonic/intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux diseases</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer/peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other : Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pancreatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Chest pain (non-cardiac or non-specific)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Fatigue/Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Fever/Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic conditions : Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Allergy to metal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Contrast media allergy/reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity/drug allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hypersensitivity/allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bone and joint infections</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Deep sternal wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Flu/influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Genitourinary infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Joint infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other : Infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Vein harvest site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Catheter site bleeding</sub_title>
                <description>Percutaneous coronary intervention (PCI) complications: access site complications</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Catheter site hematoma</sub_title>
                <description>Percutaneous coronary intervention (PCI) complications: access site complications</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <description>Percutaneous coronary intervention (PCI) complications: access site complications</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <description>Percutaneous coronary intervention (PCI) complications: access site complications</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Catheter site swelling</sub_title>
                <description>Percutaneous coronary intervention (PCI) complications: access site complications</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other : Percutaneous coronary intervention (PCI) complications</sub_title>
                <description>Percutaneous coronary intervention (PCI) complications: access site complications</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Blood creatinine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Elevated cardiac enzymes</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hyperlipidemia/hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other abnormal blood test</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Backpain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Joint or tendon disease/disorder</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other : Musculoskeletal disorder</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm/cancer : Blood or lymphatic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Neoplasm/cancer : Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Neoplasm/cancer : Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Neoplasm/cancer : Nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Neoplasm/cancer : Reproductive system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Neoplasm/cancer : Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Neoplasm/cancer : Skin or subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Neoplasm/cancer : Urinary</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other :Neoplasm/cancer</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident (CVA)</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other : Neurological/psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Seizure/convulsion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Syncope/fainting/loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack (TIA)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Mental status change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Psychiatric disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other : Renal and urinary disorder</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Renal insufficiency/impairment</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Urinary stone/calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>COPD (chronic obstructive pulmonary disease)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Dyspnea/shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other : Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Respiratory tract bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Claudication</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Dissection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other : Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Peripheral artery disease/peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Peripheral nerve lesion/injury (including peripheral neuropathy)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Thrombosis (non stent/non-coronary)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Vascular occlusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="780" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="816" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Retroperitoneal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Abrupt closure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Angina pectoris (includes atypical angina and cardiac chest pain)</sub_title>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Asystole</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="198" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardiac functional test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardiac valve disorder/disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Conduction disorder (including atrioventricular block (AV block, bundle branch block(BBB))</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary arteriospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery in-stent restenosis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery perforation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery reocclusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary stent thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Electrocardiogram (ECG) abnormal</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Coronary artery graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>No-reflow phenomenon/slow flow</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Plaque shift (tissue breakdown associated with device)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia (sustained)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Colonic/intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer/peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux diseases</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disease</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pancreatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Chest pain (non-cardiac or non-specific)</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Fatigue/Weakness</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Fever/Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to metal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Contrast media allergy/reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity/drug allergy</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hypersensitivity/allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bone and joint infections</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Flu/influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Genitourinary infection</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Vein harvest site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Deep sternal wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Catheter site hematoma</sub_title>
                <description>Percutaneous coronary intervention (PCI) complications: access site complications</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cathether site bleeding</sub_title>
                <description>Percutaneous coronary intervention (PCI) complications: access site complications</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <description>Percutaneous coronary intervention (PCI) complications: access site complications</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <description>Percutaneous coronary intervention (PCI) complications: access site complications</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Catheter site swelling</sub_title>
                <description>Percutaneous coronary intervention (PCI) complications: access site complications</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>Percutaneous coronary intervention (PCI) complications: access site complications</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Blood creatinine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia/hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other abnormal blood test</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Elevated cardiac enzymes</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Backpain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Joint or tendon disease/disorder</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Joint infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm/cancer : Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Neoplasm/cancer : Urinary</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Neoplasm/cancer : Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Neoplasm/cancer : Skin or subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Neoplasm/cancer : Blood or lymphatic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Neoplasm/cancer : Nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Neoplasm/cancer : Reproductive system</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Neoplasm/cancer : Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Neoplasm/cancer : Other</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident (CVA)</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Seizure/convulsion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Syncope/fainting/loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack (TIA)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other : Neurological/psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Mental status change (including coma)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Psychiatric disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Renal insufficiency/impairment</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Urinary stone/calculus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Respiratory tract bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>COPD (chronic obstructive pulmonary disease)</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Dyspnea/shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Claudication</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Peripheral artery disease/peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Peripheral nerve lesion/injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Thrombosis (non stent/non-coronary)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Vascular occlusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="957"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="948"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="957"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rhonda Hensley, Clinical Project Manager</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>+1 828-559-0080</phone>
      <email>rhonda.hensley@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

